Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanjing Legend Biotech Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 3 art units, giving each matter a distinct examination pathway.
GILL, RACHEL B is the busiest examiner, with 1 pending matter. Counsel should use matter-specific prosecution strategies while monitoring consistent treatment of recurring biotechnology concepts and claim language.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 16d |
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 23d overdue |
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 16d |
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | 1671 | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 1644 | §103DP | Final Rejection | 23d overdue | Pending | May 30, 2023 |
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | 16d | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Legend Biotech Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Rachel B Gill has the most, with 1 of Nanjing Legend Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
